Table 2 Definition of metabolic health in included studies.
Author, years, country | Abdominal obesity (WC or WHR) | Elevated triglycerides or lipid-lowering medication | Reduced HDL cholesterol or cholesterol-lowering medication use | Abnormal glucose metabolism, HbA1c levels, diabetes, or antidiabetic drug treatment | Elevated blood pressure - hypertension or antihypertensive medication | High C-peptide level | Homoeostatic Model Assessment for Insulin Resistance | C-reactive protein |
|---|---|---|---|---|---|---|---|---|
Mahamat-saleh et al. [19] | ✓ | |||||||
Gunter et al. [16] | ✓ | |||||||
Murphy et al. [20] | ✓ | |||||||
Kabat et al. [49] | ✓ | ✓ | ✓ | ✓ | ||||
Kliemann et al. [18] | ✓ | |||||||
Moore et al. [24] | ✓ | |||||||
Park et al. [54], USA | ✓ | ✓ | ✓ | ✓ | ||||
Park et al. [22] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Kim et al. [50] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Kim et al. [17] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Chung et al. [15] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Hashimoto et al. [48] | ✓ | ✓ | ✓ | ✓ | ||||
Cao et al. [21] | ✓ | ✓ | ✓ | ✓ | ||||
Park et al. [54] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Shin et al. [56] | ✓ | ✓ | ✓ | |||||
Shao et al. [33] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Nguyen et al. [31] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Lin et al. [41] | ✓ | ✓ | ✓ | ✓ | ||||
Liang et al. [52] | ✓ | ✓ | ✓ | ✓ | ||||
Lee et al. [28] | ✓ | ✓ | ✓ | |||||
Kwon et al. [51] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Kabat et al. [23] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Cho et al. [45] | ✓ | ✓ | ✓ | ✓ | ||||
Arnlov et al. [40] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Pasqual et al. [30] | ✓ | ✓ | ✓ | ✓ | ||||
Reeves et al. [55] | ✓ | ✓ | ✓ | |||||
Dibaba et al. [47] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Cho et al. [46] | ✓ | ✓ | ✓ | ✓ | ||||
Sun et al. [34] | ✓ | ✓ | ✓ | |||||
Moon et al. [29] | ✓ | ✓ | ✓ | ✓ | ✓ | |||
Park et al. [22] | ✓ | ✓ | ✓ | ✓ | ✓ |
